The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma.
Chie IshikawaNaoki MoriPublished in: Investigational new drugs (2020)
Primary effusion lymphoma (PEL), caused by Kaposi's sarcoma-associated herpesvirus (KSHV), presents as a lymphomatous effusion in body cavities and has a poor prognosis. The anti-malaria drug, artesunate, possesses anti-neoplastic potential. Therefore, we aimed to investigate its effect on KSHV-infected PEL cell lines. Artesunate inhibited cell growth and viability of PEL cells, but its effect on peripheral blood mononuclear cells was less pronounced. Artesunate induced G1 phase arrest by downregulating cyclin D1/D2, CDK2/6 and c-Myc. Artesunate increased reactive oxygen species and DNA damage, but did not affect the expression of latent and lytic genes of KSHV. It exhibited cytotoxicity through caspase-dependent and -independent pathways and reduced Bcl-xL, survivin, XIAP and c-IAP1/2 levels. Furthermore, artesunate suppressed NF-κB and AP-1 by inhibiting IκB kinase and IκBα phosphorylation as well as JunB expression. Finally, artesunate treatment attenuated PEL development in mice. Our data support that artesunate is a potential drug for PEL treatment.
Keyphrases
- poor prognosis
- long non coding rna
- dna damage
- cell cycle
- reactive oxygen species
- induced apoptosis
- signaling pathway
- oxidative stress
- cell cycle arrest
- cell death
- emergency department
- type diabetes
- plasmodium falciparum
- diffuse large b cell lymphoma
- gene expression
- genome wide
- electronic health record
- skeletal muscle
- adipose tissue
- high glucose
- machine learning
- inflammatory response
- immune response
- tyrosine kinase
- risk assessment
- smoking cessation